TP53 and in situ carcinoma: ICC markers such as CK14 and CK20, ProEx C (39), and markers for cell proliferation such as Ki-67, p16INK4a, and p53 have been used as an objective immunostaining marker for distinguishing carcinoma in situ from non-neoplastic urothelium.